Dong Ho Lee1, Se Hyung Kim2, Seock-Ah Im3, Do-Youn Oh3, Tae-Yong Kim3, Joon Koo Han1. 1. Department of Radiology, Seoul National University Hospital, 28, Yeongon-dong, Jongno-gu, Seoul, 110-744, Korea. 2. Department of Radiology, Seoul National University Hospital, 28, Yeongon-dong, Jongno-gu, Seoul, 110-744, Korea. shkim7071@gmail.com. 3. Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Abstract
OBJECTIVES: To investigate usefulness of multiparametric fully integrated 18-FDG PET/MRI in predicting treatment response after chemotherapy for unresectable advanced gastric cancers (AGCs). METHODS: Eleven patients with unresectable AGCs underwent multiparametric 18-FDG PET/MRI examinations prior to chemotherapy. Perfusion parameters obtained via dynamic contrast-enhanced MRI, apparent diffusion coefficient values from diffusion-weighted images, and maximum standardized uptake values (SUVmax) from 18-FDG PET were measured. For parameters obtained from 18-FDG PET/MRI data, interobserver agreement was obtained using intraclass correlation coefficients (ICC) and chemotherapy response relationship was evaluated using the Mann-Whitney test and receiver operating characteristic analysis. RESULTS: After chemotherapy, six patients were classified into the responder group and five patients into the non-responder group. For all parameters, moderate to nearly perfect agreement was achieved (ICC = 0.452-0.911). K (trans) values (P = 0.018) and initial area under the curves (iAUCs) (P = 0.045) of gastric cancers were significantly higher in responder group than in non-responder group. The area under the curve was 0.917 for K (trans) and 0.867 for iAUC. However, SUVmax values were not significantly different between the two groups. CONCLUSION: Multiparametric approach using fully integrated 18-FDG PET/MRI was shown to be feasible for patients with unresectable gastric cancers. In addition, K (trans) and iAUC values can be used as early predictive markers for chemotherapy response. KEY POINTS: • Multiparametric 18-FDG PET/MRI is feasible for patients with unresectable advanced gastric cancer • K (trans) and iAUC were significantly higher in the responder group of patients • K (trans) , iAUC can be utilized as early predictive markers for chemotherapeutic response.
OBJECTIVES: To investigate usefulness of multiparametric fully integrated 18-FDG PET/MRI in predicting treatment response after chemotherapy for unresectable advanced gastric cancers (AGCs). METHODS: Eleven patients with unresectable AGCs underwent multiparametric 18-FDG PET/MRI examinations prior to chemotherapy. Perfusion parameters obtained via dynamic contrast-enhanced MRI, apparent diffusion coefficient values from diffusion-weighted images, and maximum standardized uptake values (SUVmax) from 18-FDG PET were measured. For parameters obtained from 18-FDG PET/MRI data, interobserver agreement was obtained using intraclass correlation coefficients (ICC) and chemotherapy response relationship was evaluated using the Mann-Whitney test and receiver operating characteristic analysis. RESULTS: After chemotherapy, six patients were classified into the responder group and five patients into the non-responder group. For all parameters, moderate to nearly perfect agreement was achieved (ICC = 0.452-0.911). K (trans) values (P = 0.018) and initial area under the curves (iAUCs) (P = 0.045) of gastric cancers were significantly higher in responder group than in non-responder group. The area under the curve was 0.917 for K (trans) and 0.867 for iAUC. However, SUVmax values were not significantly different between the two groups. CONCLUSION: Multiparametric approach using fully integrated 18-FDG PET/MRI was shown to be feasible for patients with unresectable gastric cancers. In addition, K (trans) and iAUC values can be used as early predictive markers for chemotherapy response. KEY POINTS: • Multiparametric 18-FDG PET/MRI is feasible for patients with unresectable advanced gastric cancer • K (trans) and iAUC were significantly higher in the responder group of patients • K (trans) , iAUC can be utilized as early predictive markers for chemotherapeutic response.
Authors: Katja Ott; Ken Herrmann; Florian Lordick; Hinrich Wieder; Wolfgang A Weber; Karen Becker; Andreas K Buck; Martin Dobritz; Ulrich Fink; Kurt Ulm; Tibor Schuster; Markus Schwaiger; Jörg-Rüdiger Siewert; Bernd J Krause Journal: Clin Cancer Res Date: 2008-04-01 Impact factor: 12.531
Authors: Francesca Di Fabio; Carmine Pinto; Fabiola L Rojas Llimpe; Stefano Fanti; Paolo Castellucci; Ciro Longobardi; Vita Mutri; Chiara Funaioli; Francesca Sperandi; Stefania Giaquinta; Andrea A Martoni Journal: Gastric Cancer Date: 2007-12-25 Impact factor: 7.370
Authors: P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff Journal: J Magn Reson Imaging Date: 1999-09 Impact factor: 4.813
Authors: Alicia S Borggreve; Lucas Goense; Hylke J F Brenkman; Stella Mook; Gert J Meijer; Frank J Wessels; Marcel Verheij; Edwin P M Jansen; Richard van Hillegersberg; Peter S N van Rossum; Jelle P Ruurda Journal: Br J Radiol Date: 2019-03-05 Impact factor: 3.039
Authors: D L Bailey; B J Pichler; B Gückel; H Barthel; A J Beer; R Botnar; R Gillies; V Goh; M Gotthardt; R J Hicks; R Lanzenberger; C la Fougere; M Lentschig; S G Nekolla; T Niederdraenk; K Nikolaou; J Nuyts; D Olego; K Åhlström Riklund; A Signore; M Schäfers; V Sossi; M Suminski; P Veit-Haibach; L Umutlu; M Wissmeyer; T Beyer Journal: Mol Imaging Biol Date: 2016-10 Impact factor: 3.488
Authors: D L Bailey; B J Pichler; B Gückel; G Antoch; H Barthel; Z M Bhujwalla; S Biskup; S Biswal; M Bitzer; R Boellaard; R F Braren; C Brendle; K Brindle; A Chiti; C la Fougère; R Gillies; V Goh; M Goyen; M Hacker; L Heukamp; G M Knudsen; A M Krackhardt; I Law; J C Morris; K Nikolaou; J Nuyts; A A Ordonez; K Pantel; H H Quick; K Riklund; O Sabri; B Sattler; E G C Troost; M Zaiss; L Zender; Thomas Beyer Journal: Mol Imaging Biol Date: 2018-02 Impact factor: 3.488